How long should dual antiplatelet therapy be continued?

Duration of Dual Antiplatelet Therapy (DAPT)

For patients with acute coronary syndrome (ACS), DAPT should be continued for 12 months as the default duration, regardless of whether they undergo PCI, CABG, or medical management alone 1, 2.

Clinical Context-Specific Recommendations

Acute Coronary Syndrome (ACS)

The 12-month standard applies universally across all ACS management strategies:

• ACS with PCI: P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) plus aspirin for at least 12 months after BMS or DES implantation 1
• ACS with medical therapy alone: Continue P2Y12 inhibitor (ticagrelor or clopidogrel preferred) for 12 months 1, 2
• ACS with CABG: Resume P2Y12 inhibitor after surgery to complete 12 months total DAPT duration 1
• STEMI with fibrinolysis: Minimum 14 days of clopidogrel (mandatory), ideally extended to 12 months 1

Stable Coronary Artery Disease (CAD) with PCI

DAPT duration is significantly shorter: 1-6 months depending on bleeding risk 2. The stent type (BMS vs DES) should not dictate duration—base the decision on individual ischemic versus bleeding risk assessment 2.

Risk-Based Duration Modification

Shorten to 6 Months When:

• High bleeding risk exists (PRECISE-DAPT score ≥25) 2
• Patient requires oral anticoagulation 1
• Major intracranial surgery planned 1
• Significant overt bleeding develops 1

Critical caveat: In ACS patients at high bleeding risk, 6 months may be considered, but this represents a compromise—12 months remains the evidence-based target 2.

Extend Beyond 12 Months When:

• Patient has tolerated DAPT without bleeding complications AND
• Patient is NOT at high bleeding risk (no prior bleeding on DAPT, no coagulopathy, no oral anticoagulant use) AND
• High ischemic risk features present:
  • Prior MI or stent thrombosis 1
  • Complex PCI procedure 2
  • Peripheral arterial disease 2
  • Multivessel disease with incomplete revascularization 2

This extension is a Class IIb recommendation (may be reasonable), not a mandate 1.

P2Y12 Inhibitor Selection

For ACS patients:

• First choice: Ticagrelor or prasugrel (Class IIa) 1
• Use clopidogrel when: Ticagrelor/prasugrel contraindicated, patient requires oral anticoagulation, or prior stroke/TIA (prasugrel contraindicated) 2

For stable CAD patients:

• Default: Clopidogrel 2

Aspirin Dosing

Daily aspirin dose: 75-100 mg (typically 81 mg in US practice) throughout DAPT duration 1, 2. Higher doses increase bleeding without improving efficacy.

Triple Therapy (DAPT + Oral Anticoagulation)

Maximum duration: 6 months, or discontinue at hospital discharge based on ischemic versus bleeding risk balance 2. Do NOT use ticagrelor or prasugrel in this setting—clopidogrel only 2.

Common Pitfalls to Avoid

1. Do not automatically extend DAPT to 12 months in stable CAD patients—this is appropriate only for ACS 2
2. Do not use stent type to determine duration—newer-generation DES do not require longer DAPT than BMS 2
3. Do not stop DAPT within first month for elective surgery unless absolutely necessary 2
4. Reassess DAPT regimen dynamically—if actionable bleeding occurs, reconsider type, dose, and duration 2

Bleeding Mitigation Strategies

While on DAPT, implement these measures to reduce bleeding risk:

• Proton pump inhibitor (PPI) co-administration (mandatory) 2
• Radial over femoral access for procedures 2
• Low-dose aspirin (75-100 mg) 2
• Address modifiable bleeding risk factors 2

The evidence base: The 12-month ACS recommendation stems primarily from CURE, PLATO, and TRITON-TIMI 38 trials, though notably CURE's average duration was 9 months, not 12 1. The 2017 ESC and 2016 ACC/AHA guidelines represent the most authoritative current guidance, emphasizing individualized risk assessment over rigid protocols 2.